U.S. Regulators Call For Pause in Johnson & Johnson Vaccine

The U.S. is recommending a “pause” in the administration of the single-dose Johnson & Johnson COVID-19 vaccine to investigate reports of potentially dangerous blood clots. This, after six people in the U.S. developed a rate blood clotting disorder following the vaccine.

The FDA is making the recommendation “out of an abundance of caution,” adding that the blood clotting in just a handful of recipients is extremely rare.

In a joint statement with the Centers for Disease Control and Prevention, the FDA said, “COVID-19 vaccine safety is a top priority for the federal government and we take all reports of health problems very seriously. People who have received the J&J vaccine who develop severe headache, abdominal pain, leg pain, or shortness of breath within three weeks after vaccination should contact their health care provider,” the statement read.

- Advertisement -

Shares of Johnson & Johnson were down nearly 3% in pre-market trading on Tuesday after closing up in Monday’s session.

JOIN TRISH REGAN’S PRIVATE GROUP 

- Advertisement -

Related Articles

Stay Connected

165,174FansLike
709,112FollowersFollow
41,600SubscribersSubscribe
- Advertisement -

Latest Articles

Get The Full Story From Me

Conservative Media is under attack from Big Tech. Please join my 100% FREE NEWSLETTER.